Mostrar el registro sencillo del ítem

dc.contributor.authorJódar-Sánchez, Francisco 
dc.contributor.authorCarrasco-Hernández, Laura
dc.contributor.authorNúñez-Benjumea, Francisco
dc.contributor.authorMesa González, Marco A.
dc.contributor.authorMoreno Conde, Jesús
dc.contributor.authorParra-Calderón, Carlos L.
dc.contributor.authorFernandez-Luque, Luis
dc.contributor.authorHors-Fraile, Santiago
dc.contributor.authorCivit, Antón
dc.contributor.authorBamidis, Panagiotis
dc.contributor.authorOrtega Ruiz, Francisco
dc.date.accessioned2024-09-27T09:08:35Z
dc.date.available2024-09-27T09:08:35Z
dc.date.issued2018
dc.identifier.citationJódar-Sánchez, F., Carrasco Hernández, L., Núñez-Benjumea, F. J., Mesa González, M. A., Moreno Conde, J., Parra Calderón, C. L., Fernandez-Luque, L., Hors-Fraile, S., Civit, A., Bamidis, P., & Ortega-Ruiz, F. (2018). Using the Social-Local-Mobile App for Smoking Cessation in the SmokeFreeBrain Project: Protocol for a Randomized Controlled Trial. JMIR research protocols, 7(12), e12464. https://doi.org/10.2196/12464es_ES
dc.identifier.urihttps://hdl.handle.net/10630/33615
dc.description.abstractObjective: We present a study protocol of a 12-month randomized open-label parallel-group trial whose primary objective is to analyze the efficacy and efficiency of usual psychopharmacological therapy plus the Social-Local-Mobile app (intervention group) applied to the smoking cessation process compared with usual psychopharmacological therapy alone (control group). Methods: The target population consists of adult smokers (both male and female) attending the Smoking Cessation Unit at Virgen del Rocío University Hospital, Seville, Spain. Social-Local-Mobile is an innovative intervention based on mobile technologies and their capacity to trigger behavioral changes. The app is a complement to pharmacological therapies to quit smoking by providing personalized motivational messages, physical activity monitoring, lifestyle advice, and distractions (minigames) to help overcome cravings. Usual pharmacological therapy consists of bupropion (Zyntabac 150 mg) or varenicline (Champix 0.5 mg or 1 mg). The main outcomes will be (1) the smoking abstinence rate at 1 year measured by means of exhaled carbon monoxide and urinary cotinine tests, and (2) the result of the cost-effectiveness analysis, which will be expressed in terms of an incremental cost-effectiveness ratio. Results: Of 548 patients identified using the hospital's electronic records system, we excluded 308 patients: 188 declined to participate and 120 did not meet the inclusion criteria. A total of 240 patients were enrolled: the control group (n=120) will receive usual psychopharmacological therapy, while the intervention group (n=120) will receive usual psychopharmacological therapy plus the So-Lo-Mo app. Conclusions: Social networks and mobile technologies influence our daily lives and, therefore, may influence our smoking habits as well.es_ES
dc.description.sponsorshipThe research study is funded by H2020 European Commission project (Grant Agreement 681120), as part of the SmokeFreeBrain project. Further information about the project can be found on the SmokeFreeBrain project website (www.smokefreebrain.eu).es_ES
dc.language.isoenges_ES
dc.publisherJMIR Publications, Inces_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectTabaquismo - Tratamientoes_ES
dc.subjectEnsayos clínicoses_ES
dc.subject.otherCesación tabáquicaes_ES
dc.subject.otherAplicaciones móvileses_ES
dc.subject.otherEvaluación económicaes_ES
dc.subject.otherProtocolo de estudioes_ES
dc.subject.otherEnsayo clínico aleatorizadoes_ES
dc.titleUsing the Social-Local-Mobile App for Smoking Cessation in the SmokeFreeBrain Project: Protocol for a Randomized Controlled Triales_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.centroFacultad de Ciencias Económicas y Empresarialeses_ES
dc.identifier.doi10.2196/12464
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem